AR003136A1 - Peptidos de dolastatin, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar dichas composiciones farmaceuticas. - Google Patents
Peptidos de dolastatin, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar dichas composiciones farmaceuticas.Info
- Publication number
- AR003136A1 AR003136A1 ARP960102980A AR10298096A AR003136A1 AR 003136 A1 AR003136 A1 AR 003136A1 AR P960102980 A ARP960102980 A AR P960102980A AR 10298096 A AR10298096 A AR 10298096A AR 003136 A1 AR003136 A1 AR 003136A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- tert
- methyl
- butylglycyl
- norvalyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229930188854 dolastatin Natural products 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- -1 2-tert-butylglycyl Chemical group 0.000 abstract 17
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 2
- 229950003188 isovaleryl diethylamide Drugs 0.000 abstract 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000002114 valyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000001980 alanyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen nuevos derivados de dolastatin de fórmula: R1R2N-CHX-CO-A-B-D-E-(F)t-K (I), en donde R1 es metilo, etilo, o isopropilo; R2es hidrógeno, metilo, o etilo; R1-N-R2 juntos pueden formar un anillo pirrolidínico;A es un resto valilo, isoleucilo, leucilo, 2-terbutil-glicilo,2-etilglicilo, norleucilo o norvalilo; B es un resto N-metil-valilo-leucilo- isoleucilo-norvalilo-norleucilo-2-terbutilglicilo-3-ter-butilalanilo ó -2-etilglicilo; D es un resto 3,4-deh idroprolilo 4-fluoroprolilo,4,4-difluoroprolilo, azetidina-2-carbonilo,3-metil prolilo,4-metilprolilo, ó 5-metilprolilo; E es unresto prolilo, homoprolilo, hidroxiprolilo o tiazolidina-4-carbonilo; F es un resto valilo, 2-ter-butilglicilo,isoleuci lo, leucilo, 2-ciclohexilglicilo,norleucilo, norvalilo, neopentilglicilo, alanilo, beta-alanilo, o amino isobutiroilo; X es alquilo (preferentemente C2-5), ciclopropilo,o ciclopentilo;t es 0,ó 1; y K es alcoxi(preferentemente C1-4), bencilox i o una mitad de amina sustituida o no sustituida; y las sales de ellos con ácidosfisiológicamente tolerados. Dichos compuestos (I), de naturaleza peptídica, son útiles para el tratamiento de los tumores enmamíferos. Se describen, además,el pro cedimiento para preparar dichos compuestos, las composiciones farmacéuticas que los contienen y las aplicaciones de estos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/472,453 US5831002A (en) | 1992-05-20 | 1995-06-07 | Antitumor peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003136A1 true AR003136A1 (es) | 1998-07-08 |
Family
ID=23875567
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102981A AR003427A1 (es) | 1995-06-07 | 1996-06-06 | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. |
| ARP960102980A AR003136A1 (es) | 1995-06-07 | 1996-06-06 | Peptidos de dolastatin, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar dichas composiciones farmaceuticas. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102981A AR003427A1 (es) | 1995-06-07 | 1996-06-06 | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5831002A (es) |
| EP (2) | EP0832104B1 (es) |
| JP (2) | JP4221062B2 (es) |
| KR (2) | KR100437986B1 (es) |
| CN (2) | CN1182153C (es) |
| AR (2) | AR003427A1 (es) |
| AT (2) | ATE224910T1 (es) |
| AU (2) | AU725164B2 (es) |
| BG (2) | BG102125A (es) |
| BR (2) | BR9609424A (es) |
| CA (2) | CA2219819C (es) |
| CO (2) | CO4700526A1 (es) |
| CZ (2) | CZ293682B6 (es) |
| DE (2) | DE69623992T2 (es) |
| DK (2) | DK0871656T3 (es) |
| ES (2) | ES2186783T3 (es) |
| HR (2) | HRP960257A2 (es) |
| HU (2) | HU228073B1 (es) |
| IL (2) | IL122215A (es) |
| MX (2) | MX9709146A (es) |
| MY (2) | MY119042A (es) |
| NO (2) | NO317670B1 (es) |
| NZ (2) | NZ310443A (es) |
| PL (2) | PL185762B1 (es) |
| PT (2) | PT832104E (es) |
| RO (2) | RO119783B1 (es) |
| SI (2) | SI0871656T1 (es) |
| SK (1) | SK282466B6 (es) |
| TR (2) | TR199701545T1 (es) |
| TW (2) | TW508357B (es) |
| UA (2) | UA46776C2 (es) |
| WO (2) | WO1996040751A1 (es) |
| ZA (2) | ZA964710B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807984A (en) * | 1995-11-09 | 1998-09-15 | Basf Aktienegesellschaft | Oligopeptides, the preparation and use thereof |
| TW474946B (en) * | 1995-12-15 | 2002-02-01 | Basf Ag | Novel compounds, the preparation and use thereof |
| US20010009901A1 (en) * | 1996-12-11 | 2001-07-26 | Basf Aktiengesellschaft Germany | Antineoplastic peptides |
| US5965537A (en) * | 1997-03-10 | 1999-10-12 | Basf Aktiengesellschaft | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
| US6103698A (en) * | 1997-03-13 | 2000-08-15 | Basf Aktiengesellschaft | Dolastatin-15 derivatives in combination with taxanes |
| US6143721A (en) | 1997-07-18 | 2000-11-07 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
| US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
| US5985837A (en) * | 1998-07-08 | 1999-11-16 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
| CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| CN1327766C (zh) | 2001-04-27 | 2007-07-25 | 宝洁公司 | 用于控制生物膜的化合物、组合物和方法 |
| AU2002359792A1 (en) * | 2001-12-18 | 2003-06-30 | Proteologics, Inc. | Methods and compositions for the inhibition of viral release |
| AU2003224644A1 (en) * | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| US20080292616A1 (en) * | 2005-08-19 | 2008-11-27 | Government Of The United Of America, Represented By The Secretary, Department Of Health And.... | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same |
| EP1973928A2 (en) * | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
| EP2024362A4 (en) | 2006-05-16 | 2012-01-25 | Pharmascience Inc | BINDING COMPOUNDS TO THE IAP BIR DOMAIN |
| CL2007002166A1 (es) * | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
| KR101172044B1 (ko) * | 2007-04-12 | 2012-08-08 | 시노팜 타이완 리미티드 | 갈란타민의 제조 방법 |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| CN103380132B (zh) | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP3470413A3 (en) * | 2011-05-27 | 2019-08-07 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| US20250281630A1 (en) | 2021-09-03 | 2025-09-11 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US4879278A (en) * | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| AU662551B2 (en) * | 1991-08-09 | 1995-09-07 | Teikoku Hormone Mfg. Co., Ltd. | Novel tetrapeptide derivative |
| WO1993023424A1 (en) * | 1992-05-20 | 1993-11-25 | Basf Aktiengesellschaft | Derivatives of dolastatin |
| US5530097A (en) * | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
-
1995
- 1995-06-07 US US08/472,453 patent/US5831002A/en not_active Expired - Lifetime
-
1996
- 1996-06-03 ES ES96918660T patent/ES2186783T3/es not_active Expired - Lifetime
- 1996-06-03 EP EP96918660A patent/EP0832104B1/en not_active Expired - Lifetime
- 1996-06-03 EP EP96918661A patent/EP0871656B1/en not_active Expired - Lifetime
- 1996-06-03 SI SI9630550T patent/SI0871656T1/xx unknown
- 1996-06-03 AT AT96918661T patent/ATE224910T1/de active
- 1996-06-03 KR KR1019970709064A patent/KR100437986B1/ko not_active Expired - Fee Related
- 1996-06-03 HU HU9801817A patent/HU228073B1/hu not_active IP Right Cessation
- 1996-06-03 DK DK96918661T patent/DK0871656T3/da active
- 1996-06-03 PT PT96918660T patent/PT832104E/pt unknown
- 1996-06-03 NZ NZ310443A patent/NZ310443A/en not_active IP Right Cessation
- 1996-06-03 BR BR9609424-9A patent/BR9609424A/pt not_active Application Discontinuation
- 1996-06-03 AU AU61241/96A patent/AU725164B2/en not_active Ceased
- 1996-06-03 PL PL96323723A patent/PL185762B1/pl unknown
- 1996-06-03 BR BR9609423A patent/BR9609423A/pt not_active Application Discontinuation
- 1996-06-03 IL IL12221596A patent/IL122215A/xx not_active IP Right Cessation
- 1996-06-03 UA UA98010070A patent/UA46776C2/uk unknown
- 1996-06-03 MX MX9709146A patent/MX9709146A/es unknown
- 1996-06-03 TR TR97/01545T patent/TR199701545T1/xx unknown
- 1996-06-03 JP JP50013297A patent/JP4221062B2/ja not_active Expired - Fee Related
- 1996-06-03 WO PCT/EP1996/002392 patent/WO1996040751A1/en not_active Ceased
- 1996-06-03 KR KR1019970709063A patent/KR100437985B1/ko not_active Expired - Fee Related
- 1996-06-03 CN CNB961944684A patent/CN1182153C/zh not_active Expired - Fee Related
- 1996-06-03 NZ NZ310444A patent/NZ310444A/xx not_active IP Right Cessation
- 1996-06-03 SK SK1653-97A patent/SK282466B6/sk not_active IP Right Cessation
- 1996-06-03 CZ CZ19973763A patent/CZ293682B6/cs not_active IP Right Cessation
- 1996-06-03 DE DE69623992T patent/DE69623992T2/de not_active Expired - Lifetime
- 1996-06-03 SI SI9630539T patent/SI0832104T1/xx unknown
- 1996-06-03 CA CA002219819A patent/CA2219819C/en not_active Expired - Fee Related
- 1996-06-03 DE DE69623472T patent/DE69623472T2/de not_active Expired - Lifetime
- 1996-06-03 JP JP50013197A patent/JP3957751B2/ja not_active Expired - Fee Related
- 1996-06-03 AU AU61242/96A patent/AU725170B2/en not_active Ceased
- 1996-06-03 DK DK96918660T patent/DK0832104T3/da active
- 1996-06-03 UA UA98010069A patent/UA46775C2/uk unknown
- 1996-06-03 RO RO97-02254A patent/RO119783B1/ro unknown
- 1996-06-03 CZ CZ19973765A patent/CZ293683B6/cs not_active IP Right Cessation
- 1996-06-03 CN CNB961944676A patent/CN1182154C/zh not_active Expired - Fee Related
- 1996-06-03 IL IL12221696A patent/IL122216A/en not_active IP Right Cessation
- 1996-06-03 TR TR97/01544T patent/TR199701544T1/xx unknown
- 1996-06-03 CA CA002219818A patent/CA2219818C/en not_active Expired - Fee Related
- 1996-06-03 MX MX9709147A patent/MX9709147A/es unknown
- 1996-06-03 ES ES96918661T patent/ES2188759T3/es not_active Expired - Lifetime
- 1996-06-03 RO RO97-02264A patent/RO118953B1/ro unknown
- 1996-06-03 AT AT96918660T patent/ATE223431T1/de active
- 1996-06-03 PT PT96918661T patent/PT871656E/pt unknown
- 1996-06-03 PL PL96323726A patent/PL185763B1/pl unknown
- 1996-06-03 WO PCT/EP1996/002393 patent/WO1996040752A1/en not_active Ceased
- 1996-06-03 HU HU9801910A patent/HU228071B1/hu not_active IP Right Cessation
- 1996-06-03 MY MYPI96002155A patent/MY119042A/en unknown
- 1996-06-04 MY MYPI96002170A patent/MY124487A/en unknown
- 1996-06-06 AR ARP960102981A patent/AR003427A1/es active IP Right Grant
- 1996-06-06 ZA ZA9604710A patent/ZA964710B/xx unknown
- 1996-06-06 AR ARP960102980A patent/AR003136A1/es active IP Right Grant
- 1996-06-06 HR HR08/472,453A patent/HRP960257A2/hr not_active Application Discontinuation
- 1996-06-06 HR HR08/472,453A patent/HRP960277A2/hr not_active Application Discontinuation
- 1996-06-06 ZA ZA9604711A patent/ZA964711B/xx unknown
- 1996-06-07 CO CO96029749A patent/CO4700526A1/es unknown
- 1996-06-07 CO CO96029751A patent/CO4700527A1/es unknown
- 1996-06-07 TW TW085106866A patent/TW508357B/zh not_active IP Right Cessation
- 1996-10-02 TW TW085106867A patent/TW424096B/zh not_active IP Right Cessation
-
1997
- 1997-12-05 NO NO19975711A patent/NO317670B1/no not_active IP Right Cessation
- 1997-12-05 NO NO19975710A patent/NO318384B1/no not_active IP Right Cessation
- 1997-12-18 BG BG102125A patent/BG102125A/xx unknown
- 1997-12-29 BG BG102152A patent/BG102152A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003136A1 (es) | Peptidos de dolastatin, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar dichas composiciones farmaceuticas. | |
| BR0111639A (pt) | Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma | |
| YU9301A (sh) | Peptidi kao inhibitori hepatitisa c | |
| TW334418B (en) | Stilbene derivatives and pharmaceutical compositions | |
| HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR024364A1 (es) | Una composicion cosmetica para el adelgazamiento a base l-arginina, de un analogo de l-arginina, o de uno de sus derivados, que se administra por viatopica | |
| RU94028888A (ru) | Производные 1,3-замещенного циклоалкана и циклоалкена, смесь их изомеров или индивидуальные изомеры, их гидраты и соли, способ их получения и фармацевтическая композиция | |
| EA200300678A1 (ru) | Пептиды и/или белки, а также их применение для получения терапевтической и/или профилактической фармацевтической композиции | |
| LV10446A (lv) | Jauni tetrazola atvasinajumi to iegusanas panemiens un farmaceitiskas kompozicijas uz to bazes | |
| FI943931A0 (fi) | Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina | |
| ES2173626T3 (es) | Metodos y composiciones para tratar la artritis reumatoide. | |
| PT94957A (pt) | Processo para preparacao de composicoes farmaceuticas para tratamento da hipertrofia e hiperplasia cardiais e vasculares compreendendo um inibidor do enzima de conversao da angiotensina | |
| FI953566A0 (fi) | Tahdospironia tai sen analogeja sisältäviä koostumuksia | |
| ES2057802T3 (es) | Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| CA2127067A1 (fr) | Derives d'acide phosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FI973184A7 (fi) | Kombinaatioterapia HIV-infektiota varten käyttäen HIV-proteaasi-inhibi ittoria indinavir ja käänteistranskriptaasi-inhibiittoria 3TC, mahdoll isesti yhdessä AZT:n, DDI:n tai DDC:n kanssa | |
| DE3677418D1 (de) | Pharmakologisch wirksame verbindungen. | |
| ES2143107T3 (es) | Composiciones en particulas. | |
| ATE282608T1 (de) | Chinoxalindionen | |
| ES8606882A1 (es) | Procedimiento de obtencion de nuevos derivados gonadoliberi-nos y de sus sales de adicion formadas con acidos terapeuti-camente utilizables y complejos de los mismos | |
| IT1250653B (it) | Enzimi fibrinolitici ammidati e loro precursori, e processi per la loro preparazione. | |
| ZA888200B (en) | Derivatives of aminopimelic acid,their process of preparation and their application as medicaments | |
| AR003997A1 (es) | 2-[2-[(2-hidroxietil)amino]etil]-5-[[2-(metilamino)-etil]amino]indazol[4,3- gh]isoquinolin-6(2h)-ona, procesos para la preparacion del mismo y delintermediario y composiciones farmaceuticas que contienen el compuesto principal. | |
| ES2071723T3 (es) | Bencilseleniobenzoamidas de aminopiridinas y picolilaminas. | |
| DE69011692D1 (de) | Therapeutische mittel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |